Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.Explore and learn more about Conference Series : World's leading Event Organizer
As per available reports about 122 relevant journals, 50 conference proceedings, 13 conferences are presently dedicated exclusively to breathing disorder and about 2,070 articles are being published on drug metabolism.
Drug metabolism also known as xenobiotic metabolism is the biochemical modification of pharmaceutical substances or xenobiotics respectively by living organisms, usually through specialized enzymatic systems.Drug metabolism often converts lipophilic chemical compounds into more readily excreted hydrophilic products. Some drugs are chemically altered by the body.
OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.
Importance and Scope :
Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism and disposition. For example the major current and emerging markets for prescription drugs for endocrine and metabolic diseases, including hypertension, infertility, thyroid diseases, hypercholesterolemia, and obesity. Historical market data from 2004, 2005, and 2006, in addition to five-year market forecasts with compounded annual growth rates through 2011. Discusses applications as well as current and upcoming technology and trends. Provides detailed patent analysis and profiles of the major companies in the biotechnology and pharmaceutical industries that provide products for the diseases covered in this report.
The substances that result from metabolism may be inactive, or they may be similar to or different from the original drug in therapeutic activity. Some drugs, called pro-drugs, are administered in an inactive form, which is metabolized into an active form.
The resulting active metabolites produce the desired therapeutic effects. Metabolites may be metabolized further instead of being excreted from the body. The subsequent metabolites are then excreted. The major enzymatic reactions of drug metabolism are oxidation, reduction, hydrolysis, and conjugation. These reactions are biotransformation reactions. Conjugation is a synthesis reaction. A drug may have a chemical structure suitable for biotransformation via one or more of these reactions. When several reactions are possible, the result may be “competition” of several enzymes for the drug. Each enzymatic reaction results in a metabolite that itself may be further metabolized. The ratios of various metabolites depend on enzymatic reaction rates, drug concentration near the enzymes, physicochemical reactions between metabolites and enzymes, competition of multiple drugs or endogenous substrates for the same enzyme, and many other factors.
Drug metabolism is a detoxification function the human body possesses to defend itself from environment hostility. Ideally, a drug should reach the site of action intact, cure the disease, and leave the body after it completes its mission. However, drug developers often face the dilemma that a potential drug is either metabolized/excreted from the body too fast, that the drug cannot reach its therapeutic effect, or too slow, that it stays in the body for a long time, causing side effects. It elucidate the function and fate of the drug to manipulate the metabolic process of a potential drug. Most of the drugs that are available in the marketplace are administered via the oral route, which is a convenient and cost effective route of administration (Lipinski 1995; Lipinski 2000; Lipinski et al. 2001; Lipinski 2004; Abrahamsson and Lennernas 2005). Thus, oral bioavailability is one of the key considerations for discovery and development of a new chemical entity (NCE). The base year for this study is 2006. Figures are based on revenue figures at the manufacturer's level and are projected at 2006 dollar value - that is, inflation is not computed into the projection figures.
Data and trends obtained to prepare this study were derived from information obtained from pharmaceutical product managers, marketing strategists, research executives, and others at leading biotechnology and pharmaceutical companies that have products used in the treatment of the diseases covered in this report, or which have products in development for these markets.
Market Analysis:
The market for biologics was valued at $150 billion in 2011 and should reach $163 billion in 2012. Total market value is expected to reach $252 billion in 2017 after increasing at a five-year compound annual growth rate of 9%. The global market for antifungal therapeutics was valued at $10.7 billion in 2011 and is projected to reach $12.2 billion in 2016, a five-year compound annual growth rate (CAGR) of 2.7%. The global RNAi drug delivery market was worth $7 billion in 2010 and is expected to grow to nearly $24.1 billion by 2015 at a 5-year compound annual growth rate (CAGR) of 27.9%. The RNAi nucleic acid drug delivery market was worth $169.1 million globally in 2010 and by 2015 it is estimated the market will have matured. By 2015, the market for RNAi drug delivery could be around $1.1 billion globally, reflecting a compound annual growth rate (CAGR) of 45%.
2nd Therapeutic Drug Monitoring & Toxicogenomics Conference
June 9-10, 2016 Dallas, USA
8th Pharmaceutics & Novel Drug Delivery Systems Conference
March 7-9, 2016 Madrid, Spain
5th Clinical Endocrinology & Metabolism Conference
Aug 22-24, 2016 Sao Paulo, Brazil
Integrative Medicine Conference
Aug 11-13, 2016,Las Vegas, USA
Predictive, Preventive & Personalized Medicine & Molecular Diagnostics Conference
Sept 19-21, 2016,Pheonix, USA
Psychosomatic Medicine Conference
Oct 17-19, 2016 Rome, Italy
Euro-Global Summit on Toxicology & Applied Pharmacology Conference
Oct 27-29, 2016,Rome, Italy
3rd Pharmacology Conference
Aug 8-10, 2016,Birmingham, UK
5th Toxicology & Applied Pharmacology Conference
Sept 19-21, 2016,Las Vegas, USA
Toxicogenomics & Drug Monitoring Conference
August 25-27,2015 Valencia, Spain
2nd Drug Discovery & Designing Conference
October 31-November 02, 2016 Istanbul, Turkey
Drug Discovery & Therapy World Congress 2016 (4th in the Series)
May 11th - 14th, 2016, Boston, USA
Structure Based Drug Design Conference 2016
21 - 24 February 2016 Carlsbad, USA
1st SQU Int. Chem. Conference on Recent Trends in Drug Development
10 - 12 November 2015, Oman
National Medicinal Chemistry Symposium
26 - 29 June 2016 Chicago, USA
Structure Based Drug Design Conference 2016
21 - 24 February 2016 Carlsbad, USA
7th International Conference on Drug Discovery & Therapy
February 15th - 18th, 2016, Dubai, UAE
Major Drug metabolism and related Companies:
01.Green peace International
02.Bioray
03.Nosh Detox
04.Spritual River
05.ARY DISTRIBUTION INC.
06.Natures Way Elite, LLC
07.Castlrock Industries, Inc
08.Wiggle Puppy Productions
09.Acupeds
10.Spectrum Labs
11.YOUNGYOU INTERNATIONAL
12.CT Aion Tech CO.LTD
13.Natural Detox Store
14.Ovina Trade Company, Inc.
Related Societies:
1. National Acupuncture Detoxification Association
2. The George Spady Society
3. Sikkim Rehabilitation & Detoxification Society
4. California Society of Addiction Medicine
5. Drug Addicts Detoxification and Rehabilitation Society (DADRS)
6. British Natural Hygiene Society
7. International Society of Toxinology
8. African Society for Toxicological Sciences
9. Society of Environmental Toxicology and Chemistry
10.Society of Toxicology
This page will be updated regularly.
This page was last updated on November 5, 2024
